Online inquiry

IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8732MR)

This product GTTS-WQ8732MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CCR5 gene. The antibody can be applied in AIDS, Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000579.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1234
UniProt ID P51681
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8732MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4174MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ3687MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ4992MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA C4G1
GTTS-WQ1383MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ12704MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ3977MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ12674MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ8087MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW